相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Nuclear Medicine Therapy With 223Radium-dichloride for Osseous Metastases in Prostate Carcinoma
Daniel J. Wale et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2019)
JAK2/PD-L1/PD-L2 (9p24.1) amplifications in renal cell carcinomas with sarcomatoid transformation: implications for clinical management
Sounak Gupta et al.
MODERN PATHOLOGY (2019)
Genomic correlates of clinical outcome in advanced prostate cancer
Wassim Abida et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer
Anis A. Humid et al.
EUROPEAN UROLOGY (2019)
Next-Generation Sequencing Based Assessment of JAK2, PD-L1, and PD-L2 Copy Number Alterations at 9p24.1 in Breast Cancer Potential Implications for Clinical Management
Sounak Gupta et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2019)
A Somatically Acquired Enhancer of the Androgen Receptor Is a Noncoding Driver in Advanced Prostate Cancer
David Y. Takeda et al.
CELL (2018)
Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study
Rahul Aggarwal et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Cellular plasticity and the neuroendocrine phenotype in prostate cancer
Alastair H. Davies et al.
NATURE REVIEWS UROLOGY (2018)
Circulating Tumor DNA Genomics Correlate with Resistance to Abiraterone and Enzalutamide in Prostate Cancer
Matti Annala et al.
CANCER DISCOVERY (2018)
Positron Emission Tomography/Computed Tomography-Based Assessments of Androgen Receptor Expression and Glycolytic Activity as a Prognostic Biomarker forMetastatic Castration-Resistant Prostate Cancer
Josef J. Fox et al.
JAMA ONCOLOGY (2018)
Nuclear-specific AR-V7 Protein Localization is Necessary to Guide Treatment Selection in Metastatic Castration-resistant Prostate Cancer
Howard I. Scher et al.
EUROPEAN UROLOGY (2017)
Next-Generation Assessment of Human Growth Factor Receptor 2 (ERBB2) Amplification Status Clinical Validation in the Context of a Hybrid Capture-Based, Comprehensive Solid Tumor Genomic Profiling Assay
Dara S. Ross et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2017)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer
Howard I. Scher et al.
CANCER RESEARCH (2017)
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Eric G. Bluemn et al.
CANCER CELL (2017)
Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study
V. Conteduca et al.
ANNALS OF ONCOLOGY (2017)
Prospective Genomic Profiling of Prostate Cancer Across Disease States Reveals Germline and Somatic Alterations That May Affect Clinical Decision Making
Wassim Abida et al.
JCO PRECISION ONCOLOGY (2017)
Combined Tumor Suppressor Defects Characterize Clinically Defined Aggressive Variant Prostate Cancers
Ana M. Aparicio et al.
CLINICAL CANCER RESEARCH (2016)
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
Howard I. Scher et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Precision medicine at Memorial Sloan Kettering Cancer Center: clinical next-generation sequencing enabling next-generation targeted therapy trials
David M. Hyman et al.
DRUG DISCOVERY TODAY (2015)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
Treating Patients with Metastatic Castration Resistant Prostate Cancer: A Comprehensive Review of Available Therapies
E. David Crawford et al.
JOURNAL OF UROLOGY (2015)
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Philip A. Watson et al.
NATURE REVIEWS CANCER (2015)
Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation
Jonathan I. Epstein et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2014)
Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
Hsueh-Li Tan et al.
CLINICAL CANCER RESEARCH (2014)
AR-V7 and Resistance to Enzalutamide and Abiraterone in Prostate Cancer
Emmanuel S. Antonarakis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeted Next-generation Sequencing of Advanced Prostate Cancer Identifies Potential Therapeutic Targets and Disease Heterogeneity
Himisha Beltran et al.
EUROPEAN UROLOGY (2013)
Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
Jianjiong Gao et al.
SCIENCE SIGNALING (2013)
Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis
Anna Yemelyanova et al.
MODERN PATHOLOGY (2011)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Small cell carcinoma of the prostate - A morphologic and immunohistochemical study of 95 cases
Wenle Wang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2008)
Androgen-independent prostate cancer is a heterogeneous group of diseases: Lessons from a rapid autopsy program
RB Shah et al.
CANCER RESEARCH (2004)
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone
MP Roudier et al.
HUMAN PATHOLOGY (2003)
分享论文
